Clinical Trials Logo

Stage III Multiple Myeloma clinical trials

View clinical trials related to Stage III Multiple Myeloma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01816971 Active, not recruiting - Clinical trials for Stage III Multiple Myeloma

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Start date: January 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant works in treating patients with newly diagnosed multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from diving. Giving carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant may kill more cancer cells

NCT ID: NCT00410605 Active, not recruiting - Clinical trials for Refractory Multiple Myeloma

Bevacizumab, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Stage II or Stage III Multiple Myeloma

Start date: November 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving bevacizumab together with lenalidomide and dexamethasone works in treating patients with relapsed or refractory stage II or stage III multiple myeloma. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab and lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Dexamethasone may stimulate the immune system in different ways and stop cancer cells from growing. Giving bevacizumab together with lenalidomide and dexamethasone may kill more cancer cells.

NCT ID: NCT00112723 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Start date: December 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of flavopiridol and to see how well it works in treating patients with lymphoma or multiple myeloma. Drugs used in chemotherapy, such as flavopiridol, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.